Publications by authors named "C P M Verkleij"
Natural killer (NK) cells are important effector cells in antibody-based immune therapies for multiple myeloma (MM) through antibody-dependent cellular cytotoxicity. Here, we used single-cell transcriptomics, flow cytometry and functional assays to investigate the bone marrow NK cell compartment of MM patients at diagnosis and during treatment. We show reduced proportion of CD16+ cytotoxic NK cells in a subset of patients at diagnosis, which correlated with decreased cytokine production and NK cell degranulation against MM cells in the presence of the anti-CD38 antibody daratumumab.
View Article and Find Full Text PDFBackground: Autologous BCMA-specific CAR T-cell therapies have substantial activity in multiple myeloma (MM). However, due to logistical limitations and BCMA relapses, there is a need for alternatives. UCARTCS1 cells are 'off-the-shelf' allogeneic CAR T-cells derived from healthy donors targeting SLAMF7 (CS1), which is highly expressed in MM cells.
View Article and Find Full Text PDFArticle Synopsis
- Bispecific antibodies teclistamab and talquetamab show effectiveness against multiple myeloma, but their mechanisms of resistance remain unclear.
- In laboratory studies on patients' bone marrow samples, the success of these treatments was linked to the balance of T cells and regulatory T cells in the samples.
- Resistance to BsAb treatment indicates issues like low ratios of T-cells to myeloma cells and immunosuppression from Tregs, which hinder T-cell activity and reduce treatment efficacy.
Article Synopsis
- Teclistamab, a bispecific antibody targeting BCMA, shows strong effectiveness in patients with multiple myeloma but leads to a high incidence of infections due to its impact on the immune system.
- The treatment results in rapid depletion of B cells and significantly lowers levels of various immunoglobulins, impairing patients' ability to respond to vaccines.
- Utilizing intravenous immunoglobulin (IVIG) can reduce the risk of serious infections in patients on teclistamab, highlighting the importance of immunoglobulin support in managing these patients' immune health.